JP2020502066A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502066A5
JP2020502066A5 JP2019527417A JP2019527417A JP2020502066A5 JP 2020502066 A5 JP2020502066 A5 JP 2020502066A5 JP 2019527417 A JP2019527417 A JP 2019527417A JP 2019527417 A JP2019527417 A JP 2019527417A JP 2020502066 A5 JP2020502066 A5 JP 2020502066A5
Authority
JP
Japan
Prior art keywords
cancer
carcinoma
pharmaceutical composition
disease
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019527417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502066A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/062643 external-priority patent/WO2018094362A1/en
Publication of JP2020502066A publication Critical patent/JP2020502066A/ja
Publication of JP2020502066A5 publication Critical patent/JP2020502066A5/ja
Withdrawn legal-status Critical Current

Links

JP2019527417A 2016-11-21 2017-11-20 キナーゼ阻害剤としての複素環式化合物 Withdrawn JP2020502066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424978P 2016-11-21 2016-11-21
US62/424,978 2016-11-21
PCT/US2017/062643 WO2018094362A1 (en) 2016-11-21 2017-11-20 Heterocyclic compounds as kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2020502066A JP2020502066A (ja) 2020-01-23
JP2020502066A5 true JP2020502066A5 (enExample) 2021-01-07

Family

ID=62145877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527417A Withdrawn JP2020502066A (ja) 2016-11-21 2017-11-20 キナーゼ阻害剤としての複素環式化合物

Country Status (8)

Country Link
US (1) US10807966B2 (enExample)
EP (1) EP3541806A4 (enExample)
JP (1) JP2020502066A (enExample)
CN (1) CN110382481A (enExample)
AU (1) AU2017362571A1 (enExample)
CA (1) CA3082254A1 (enExample)
IL (1) IL266789A (enExample)
WO (1) WO2018094362A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220102622A (ko) * 2019-11-15 2022-07-20 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 Rock 억제제 및 이의 제조 방법과 용도
CN112979675B (zh) * 2019-12-12 2023-12-19 维眸生物科技(上海)有限公司 一种小分子含硫杂环化合物
TWI777325B (zh) * 2019-12-31 2022-09-11 財團法人工業技術研究院 β-胺基酸衍生物、含其之激酶抑制劑與醫藥組成物以及其用途
KR102758256B1 (ko) * 2019-12-31 2025-01-21 인더스트리얼 테크놀로지 리서치 인스티튜트 β-아미노산 유도체, 키나아제 억제제 및 이를 함유하는 약학 조성물
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
US11945796B2 (en) 2020-09-16 2024-04-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
JP2023543740A (ja) * 2020-09-23 2023-10-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピラゾリル-ピリミジン誘導体
AU2022320699A1 (en) 2021-07-28 2024-02-29 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
AU2024269232A1 (en) * 2023-05-09 2025-11-13 Amgen Inc. 5,6-fused and 6,6-fused bicyclic alcohols and ethers and compositions for use as 15-prostaglandin dehydrogenase modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2008011557A2 (en) * 2006-07-20 2008-01-24 Borchardt Allen J Heteroaryl inhibitors of rho kinase
CA2709883A1 (en) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
US20100093714A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20130129677A1 (en) 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
US9221808B2 (en) * 2010-04-16 2015-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
AR083855A1 (es) * 2010-11-15 2013-03-27 Abbott Lab Inhibidores de nampt y rock
JP5976778B2 (ja) * 2011-04-11 2016-08-24 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
US10392402B2 (en) * 2015-05-18 2019-08-27 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2020502066A5 (enExample)
JP2018515623A5 (enExample)
JP2019514863A5 (enExample)
KR101501785B1 (ko) 과증식성 장애 및 혈관형성과 관련된 질환 치료에 유용한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린 유도체
CN100575345C (zh) 对2型大麻素受体具有结合活性的吡啶酮衍生物
ES2988336T3 (es) Un agente antineoplásico 1-((4-(4-fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiquinolin-7-iloxi)metil)ciclopropanamina, su forma cristalina y sus sales
CN106795144B (zh) 用于调节egfr突变体激酶活性的化合物和组合物
US11919858B2 (en) Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
JP2009535335A5 (enExample)
JP2016523973A5 (enExample)
CN115803325A (zh) 一种egfr抑制剂及其制备方法和应用
AU2007284562A1 (en) Using PI3K and MEK modulators in treatments of cancer
JP2017061547A5 (enExample)
JP2020504716A5 (enExample)
WO2005035503A1 (ja) 新規イソキノリン誘導体
JP2009513703A5 (enExample)
TW201124395A (en) Therapeutic compounds and related methods of use
CA2861980C (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof
JP2015518899A5 (enExample)
US10745350B2 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
JP2019535812A5 (enExample)
JP2017526731A5 (enExample)
PH12017501989A1 (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
TW201841910A (zh) 胺吡啶衍生化合物之鹽類、其結晶形及其製備方法